Evolvable platform for programmable nanoparticle-based cancer therapies

Informazioni relative al progetto

EVO-NANO

ID dell’accordo di sovvenzione: 800983

DOI 10.3030/800983

Progetto chiuso

Data della firma CE 3 Maggio 2018

Data di avvio 1 Ottobre 2018

Data di completamento 31 Marzo 2022

Finanziato da

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Costo totale € 2 988 658,75

Contributo UE € 2 988 658,75

Coordinato da

UNIVERZITET U NOVOM SADU, POLJOPRIVREDNI FAKULTET NOVI SAD
Serbia

Risultati finali

Documents, reports (15)

Final report on MD simulations and XAI model

Final report on performed molecular dynamics simulations developed XAI model and results of XAI predictions

Evolutionary model definition and specifications

A report containing a description of the eCS approach, definition of the meta model and specification for the implementation of the meta model.

Report of the kick-off meeting

Report of the decisions from the kick-off meeting, its agenda and list of participants.

Technical/scientific review meeting documents for RP2

Draft agenda presentations and other review meeting documents before the review meeting

Technical/scientific review meeting documents for RP1

Draft agenda, presentations and other review meeting documents before the review meeting.

In vivo validation

Final report on the results of in vivo validation results of NP biodistribution pharmacokinetics toxicity and efficacy in human cancer xenograft animal models Validation will be performed by injecting previously prepared and synthesized NPs Task 32 into athymic mice

Dissemination and Exploitation Plan at the end of the first Reporting Period (RP1)

Plan for dissemination and exploitation activities that will be updated for the subsequent Reporting Periods.

eCS vascular and CSC strategies

Evolved mechanisms of NP circulation and NP-CSC interactions. The report will comprise description of experimental settings (Task 2.1), results of in silico experiments (Task 2.2) and analysis and scoring of evolved strategies (Task 2.3). The report will also provide specifications and criteria for evaluating and scoring of evolved strategies.

Web site, logo and other mass media presence

A report on launched website, logo, blog, social media channels, high-quality video presentation of the project and brochure/flyer.

Mid-term MD simulations and XAI toy model

Report on performed molecular dynamics simulations and developed XAI toy model based on data obtained from molecular dynamics simulations

eCS anti-cancer strategies

Evolved complete DDS strategies that include NP circulation transvascular NP translocation tumour penetration and NPCSC interaction The report will comprise description of experimental settings Task 21 results of in silico experiments Task 22 and analysis and scoring of evolved strategies Task 23 Report will provide specifications and criteria for evaluating and scoring of evolved strategies

Final report on communication and dissemination activities
Final in vitro validation

Report on the results of in vitro validation results of NP extravasations tumour penetration cellular uptake viability and pharmacological effect of the evolved nanoparticle strategies Validation will be performed by injecting previously prepared and synthesized NPs Task 32 into all prepared microfluidic devices Task 31

eCS endothelial and tumour strategies

Evolved mechanisms of NP endothelial and tumour penetration. The report will comprise description of experimental settings (Task 2.1), results of in silico experiments (Task 2.2) and analysis and scoring of evolved strategies (Task 2.3). The report will also provide specifications and criteria for evaluating and scoring of evolved strategies.

First in vitro validation

Report on validation of devices 1&4. Validation will be performed by injecting previously prepared and synthesized NPs (Task 3.2) into devices 1&4 (Task 3.1).

Other (3)

Mid-term eCS implementation and testing

Improved eCS platform tested documented and uploaded to the public repository Documentation will include a report on implemented improvements Task 12 and their operational testing results Task 13

Final eCS implementation and testing

Final version of the eCS platform tested documented and uploaded to the public repository Documentation will include a report on latest improvements Task 12 and their operational testing results Task 13

Initial eCS implementation and testing

eCS platform is implemented, (Task 1.2), tested (Task 1.3), documented and uploaded to the public repository.

Websites, patent fillings, videos etc. (1)

Workshop organization

Organized International Workshop: “Evolving nano-treatments of cancer”.

Open Research Data Pilot (1)

Data management plan

Delivered a first version of Data Management Plan (DMP)

Pubblicazioni

Peer reviewed articles (16)

Editorial: Computational approaches in cancer modelling

Autori: Igor Balaz, Sabine Hauert, Andrew Adamatzky
Pubblicato in: Biosystems, Numero 204, 2021, ISSN 0303-2647
Editore: Elsevier BV
DOI: 10.1016/j.biosystems.2021.104385

In silico optimization of cancer therapies with multiple types of nanoparticles applied at different times

Autori: Michail-AntisthenisTsompanas, LarryBull, AndrewAdamatzky, IgorBalaz
Pubblicato in: Computer Methods and Programs in Biomedicine, Numero 200, 2021, ISSN 0169-2607
Editore: Elsevier BV
DOI: 10.1016/j.cmpb.2020.105886

In silico modelling of cancer nanomedicine, across scales and transport barriers.

Autori: Namid R. Stillman, Marina Kovacevic, Igor Balaz & Sabine Hauert
Pubblicato in: npj Computational Materials, Numero 6, 92, 2020, ISSN 2057-3960
Editore: Nature Publishing Group
DOI: 10.1038/s41524-020-00366-8

Evolutionary computational platform for the automatic discovery of nanocarriers for cancer treatment

Autori: Namid R. Stillman; Igor Balaz; Michail-Antisthenis I. Tsompanas; Marina Kovacevic; Sepinoud Azimi; Sebastien Lafond; Andrew Adamatzky; Sabine Hauert
Pubblicato in: npj Computational Materials, Vol 7, Iss 1, Pp 1-12 (2021), Numero 2, 2021, Pagina/e 1-12, ISSN 2057-3960
Editore: Springer Nature
DOI: 10.1038/s41524-021-00614-5

The potential of nanomedicine to alter cancer stem cell dynamics: the impact of extracellular vesicles

Autori: Petra Gener , Patricia Gonzalez Callejo, Joaquín Seras-Franzoso, Fernanda Andrade, Diana Rafael, Ibane Abasolo & Simo Schwartz
Pubblicato in: Nanomedicine, Numero 15, 2020, Pagina/e 2785-2800, ISSN 1743-5889
Editore: Future Medicine Ltd.
DOI: 10.2217/nnm-2020-0099

Measuring Nanoparticle Penetration Through Bio-Mimetic Gels

Autori: Scott C McCormick, Namid Stillman, Matthew Hockley, Adam W Perriman, Sabine Hauert
Pubblicato in: International Journal of Nanomedicine, Numero 16, 2021, Pagina/e 2585–2595, ISSN 1178-2013
Editore: DovePress
DOI: 10.2147/ijn.s292131

Metameric representations on optimization of nano particle cancer treatment

Autori: Michail-Antisthenis I. Tsompanas; Larry Bull; Andrew Adamatzky; Igor Balaz
Pubblicato in: Biocybernetics and Biomedical Engineering, Numero 6, 2021, Pagina/e 352-361, ISSN 0208-5216
Editore: Polish Scientific Publishers PWN
DOI: 10.1016/j.bbe.2021.02.002

Harnessing adaptive novelty for automated generation of cancer treatments

Autori: Igor Balaz, Tara Petrić, Marina Kovacevic, Michail-Antisthenis Tsompanas, Namid Stillman
Pubblicato in: Biosystems, 2020, Pagina/e 104290, ISSN 0303-2647
Editore: Elsevier BV
DOI: 10.1016/j.biosystems.2020.104290

Toward Engineering Biosystems With Emergent Collective Functions

Autori: Thomas E. Gorochowski, Sabine Hauert, Jan-Ulrich Kreft, Lucia Marucci, Namid R. Stillman, T.-Y. Dora Tang, Lucia Bandiera, Vittorio Bartoli, Daniel O. R. Dixon, Alex J. H. Fedorec, Harold Fellermann, Alexander G. Fletcher, Tim Foster, Luca Giuggioli, Antoni Matyjaszkiewicz, Scott McCormick, Sandra Montes Olivas, Jonathan Naylor, Ana Rubio Denniss, Daniel Ward
Pubblicato in: Frontiers in Bioengineering and Biotechnology, Numero 8, 2020, ISSN 2296-4185
Editore: Frontiers
DOI: 10.3389/fbioe.2020.00705

Microvessel-on-Chip Fabrication for the In Vitro Modeling of Nanomedicine Transport

Autori: Sergio Dávila, Jean Cacheux, Isabel Rodríguez
Pubblicato in: ACS Omega, Numero 6, 2021, Pagina/e 25109–25115, ISSN 2470-1343
Editore: ACSPublications
DOI: 10.1021/acsomega.1c00735

Towards an evolvable cancer treatment simulator

Autori: Richard J. Preen, Larry Bull, Andrew Adamatzky
Pubblicato in: Biosystems, Numero 182, 2019, Pagina/e 1-7, ISSN 0303-2647
Editore: Elsevier BV
DOI: 10.1016/j.biosystems.2019.05.005

Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells

Autori: Petra Gener, Sara Montero, Helena Xandri-Monje, Zamira V. Díaz-Riascos, Diana Rafael, Fernanda Andrade, Francesc Martínez-Trucharte, Patricia González, Joaquin Seras-Franzoso, Albert Manzano, Diego Arango, Joan Sayós, Ibane Abasolo, Simo Schwartz
Pubblicato in: Nanomedicine: Nanotechnology, Biology and Medicine, Numero 24, 2020, Pagina/e 102106, ISSN 1549-9634
Editore: Elsevier BV
DOI: 10.1016/j.nano.2019.102106

Novelty search employed into the development of cancer treatment simulations

Autori: Michail-Antisthenis Tsompanas, Larry Bull, Andrew Adamatzky, Igor Balaz
Pubblicato in: Informatics in Medicine Unlocked, 2020, Pagina/e 100347, ISSN 2352-9148
Editore: Elsevier
DOI: 10.1016/j.imu.2020.100347

Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells

Autori: Gener, Rafael, Seras-Franzoso, Perez, Pindado, Casas, Arango, Fernández, Díaz-Riascos, Abasolo, Schwartz
Pubblicato in: Cancers, Numero 11/8, 2019, Pagina/e 1058, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers11081058

Mixed-monolayer functionalized gold nanoparticles for cancer treatment: Atomistic molecular dynamics simulations study

Autori: Marina Kovacevic, Igor Balaz, Domenico Marson, Erik Laurini, Branislav Jovic
Pubblicato in: Biosystems, Numero 202, 2021, ISSN 0303-2647
Editore: Elsevier BV
DOI: 10.1016/j.biosystems.2021.104354

Evolutionary Algorithms Designing Nanoparticle Cancer Treatments with Multiple Particle Types [Application Notes]

Autori: Michail-Antisthenis I. Tsompanas; Larry Bull; Andrew Adamatzky; Igor Balaz
Pubblicato in: IEEE Computational Intelligence Magazine, Numero 7, 2021, ISSN 1556-603X
Editore: Institute of Electrical and Electronics Engineers
DOI: 10.1109/mci.2021.3108306

Conference proceedings (3)

Towards open-ended evolutionary simulator for developing novel tumour drug delivery systems

Autori: Igor Balaz; Tara Petric; Namid R. Stillman
Pubblicato in: ALIFE 2021: The 2021 Conference on Artificial Life, 2021
Editore: MIT Press
DOI: 10.1162/isal_a_00435

Trail Formation Using Large Swarms of Minimal Robots

Autori: Pere Molins, Namid Stillman, Sabine Hauert
Pubblicato in: Cybernetics and Systems, Numero 50, 2019, Pagina/e 693-710
Editore: Taylor & Francis
DOI: 10.1080/01969722.2019.1677336

Utilizing Differential Evolution into optimizing targeted cancer treatments

Autori: Tsompanas, Michail-Antisthenis; Bull, Larry; Adamatzky, Andrew; Balaz, Igor
Pubblicato in: Modern Trends in Controlled Stochastic Processes, Numero 1, 2021, Pagina/e 328-340
Editore: Springer
DOI: 10.1007/978-3-030-76928-4_17

Other (2)

Haploid-Diploid Evolution: Nature's Memetic Algorithm

Autori: Tsompanas, Michail-Antisthenis; Bull, Larry; Adamatzky, Andrew; Balaz, Igor
Pubblicato in: Numero 4, 2019
Editore: arXiv

Model Exploration with Cost-Aware Learning

Autori: Stillman, Namid; Balazs, Igor; Hauert, Sabine
Pubblicato in: ArXiv Machine Learning, Numero 2, 2020
Editore: ArXiv
DOI: 10.48550/arxiv.2010.04512